Oxidants and antioxidants in idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis

Volumn , Issue , 2003, Pages 379-396

  Behr, Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955096915     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Frank L, Massaro FL. Oxygen toxicity. Am J Med 1980; 69:117–126.
2. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989; 320: 365–376.
3. Doelman CJ, Bast A. Oxygen radicals in lung pathology. Free Radic Biol Med 1990; 9:381–400.
4. Schraufstätter IU, Cochrane CG. Oxidants: Types, sources, and mechanisms of injury. In: Crystal RG, West JB, eds. The Lung, Raven Press, New York, 1991, pp. 1803–1810.
5. Moncada S, Palmer RJR, Higgs EA. Nitric oxide: physiology, and pharmacology. Pharmacol Rev 1991; 43:109–123.
6. Nathan C. Nitric oxide is a secretory product of mammalian cells. FASEB J 1992; 6:3051–3064.
7. Saleh D, Barnes PJ, Giaid A. Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1997; 155:1763–1769.
8. Carp H, Janoff A. Potential mediators of inflammation: phagocyte-derived oxidants suppress the elastase-inhibitory capacity of alpha1-proteinase inhibitor in vitro. J Clin Invest 1980; 66:987–995.
9. Swaim MW, Pizzo SV. Methionine sulfoxide and the oxidative regulation of plasma proteinase inhibitors. J Leukoc Biol 1988; 43:365–379.
10. Vogelmeier C, Biedermann T, Maier K, Behr J, Krombach F, Buhl R. Comparative loss of activity of recombinant secretory leukoprotease inhibitor and alpha(1)-protease inhibitor caused by different forms of oxidative stress. Eur Respir J 1997; 10:2114–2119.
11. Buhl R, Meyer A, Vogelmeier C. Oxidant–protease interaction in the lung. Prospects for antioxidant therapy. Chest 1996; 110(suppl):267s–272s.
12. Greenwald RA, Moy WW. Inhibition of collagen gelation by action of the superoxide radical. Arthritis Rheum 1979; 22:251–259.
13. Weiss SJ, Peppin G, Ortiz X, Ragsdale C, Test ST. Oxidative autoactivation of latent collagenase by human neutrophils. Science 1985; 227:747–749.
14. Guidarelli A, Palomba L, Cantoni O. Peroxynitrite-mediated release of arachidonic acid from PC12 cells. Br J Pharmacol 2000; 129:1539–1541.
15. Cane A, Breton M, Koumanov K, Bereziat G, Colard O. Oxidant-induced arachidonic acid release and impairment of fatty acid acylation in vascular smooth muscle cells. Am J Physiol 1998; 274:C1040–1046.
16. Winyard PG, Blake DR. Antioxidants, redox-regulated transcription factors, and inflammation. Adv Pharmacol 1997; 38:403–421.
17. Droge W, Schulze-Osthoff K, Mihm S, Galter D, Schenk H, Eck HP, Roth S, Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 1994; 8:1131–1138.
18. Harper R, Wu K, Chang MJ, Yoneda K, Pan R, Reddy SPM, Wu R. Activation of nuclear factor-kB transcriptional activation in airway epithelial cells by thioredoxin but not by N-acetyl-cysteine and glutathione. Am J Respir Cell Mol Biol 2001; 25:178–185.
19. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10:2247–2258.
20. Anderson MT, Staal FJ, Gitler C, Herzenberg LA. Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc Natl Acad Sci USA 1994; 91:11527–11531.
21. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994; 12:141–179.
22. Blake DR, Winyard PG, Marok R. The contribution of hypoxia-reperfusion injury to inflammatory synovitis: the influence of reactive oxygen intermediates on the transcriptional control of inflammation. Ann NY Acad Sci 1994; 723:308–317.
23. Heffner JE, Repine JE. Antioxidants and the lung. In: Crystal RG and West JB eds. The Lung. Raven Press, New York, 1991, pp. 1811–1820.
24. Davis WB, Pacht ER. Extracellular antioxidant defenses. In: Crystal RG, West JB, eds. The Lung. Raven Press, New York, 1991, pp. 1821–1828.
25. Cantin AM, Begin R. Glutathione and inflammatory disorders of the lung. Lung 1991; 169:123–138.
26. Cantin AM, North SL, Hubbard RC, Crystal RG. Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 1987; 63:152–157.
27. Behr J, Degenkolb B, Maier K, Braun B, Beinert T, Krombach F, Vogelmeier C, Fruhmann G. Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis. Eur Respir J 1995; 8:1286–1292.
28. Meister A, Anderson ME. Glutathione. Annu Rev Biochem 1983; 52:711–760.
29. Meister A. New aspects of glutathione biochemistry and transport–selective alteration of glutathione metabolism. Nutr Rev 1984; 42:397–410.
30. Deneke SM, Fanburg BL. Regulation of cellular glutathione. Am J Physiol 1989; 257:L163–L173.
31. Cantin AM, North SL, Fells GA, Hubbard RC, Crystal RG. Oxidant-mediated epithelial cell injury in idiopathic pulmonary fibrosis. J Clin Invest 1987; 79: 1665–1673.
32. Clement A, Chadelat K, Masliah J, Housset B, Sardet A, Grimfeld A, Tournier G. A controlled study of oxygen metabolite release by alveolar macrophages from children with interstitial lung disease. Am Rev Respir Dis 1987; 136:1424–1428.
33. Strausz J, Müller-Quernheim J, Steppling H, Ferlinz R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990; 141:124–128.
34. Jack CIA, Jackson MJ, Johnston IDA, Hind CRK. Serum indicators of free radical activity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1996; 153:1918–1923.
35. Maier KL, Leuschel L, Costabel U. Increased levels of oxidized methionine in BAL fluid proteins from patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1991; 143:271–274.
36. Behr J, Maier K, Krombach F, Adelmann-Grill B. Pathogenetic significance of reactive oxygen species in diffuse fibrosing alveolitis. Am Rev Respir Dis 1991; 144:146–150.
37. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139:370–372.
38. Arsalane K, Dubois CM, Muanz T, Begin R, Boudreau F, Asselin C, Cantin AM. Transforming growth factor-1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the GSH rate-limiting enzyme gamma-glutamyl-cysteine synthetase. Am J Cell Mol Biol 1997; 17: 599–607.
39. Rahman I, Mulier B, Gilmour PS, Watchorn T, Donaldson K, Jeffery PK, MacNee W. Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor kappaB. Biochem Pharmacol 2001; 62:787–794.
40. Rahman I, MacNee W. Oxidative stress and regulation of glutathione in lung inflammation. Eur Respir J 2000; 16:534–554.
41. Rahman I. Regulation of nuclear factor kappaB, activator protein-1, and glutathione levels by tumor necrosis factor-alpha and dexamethasone in alveolar epithelial cells. Biochem Pharmacol 2000; 60:1041–1049.
42. Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione levels and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J 2002; 19:906–911.
43. Gosset P, Wallaert B, Tonnel AB, Fourneau C. Thiol regulation of the production of TNF- alpha, IL-6 and IL-8 by human alveolar macrophages. Eur Respir J 1999; 14:98–105.
44. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 1998; 157:1301–1315.
45. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis an treatment international consensus statement. Am J Respir Crit Care Med 2000; 161:646–664.
46. American Thoracic Society, European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002; 165:277–304.
47. Murrell GAC, Francis MJO, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem J 1990; 265:659–665.
48. Lavrentiadou SN, Chan C, Kawcak TN, Ravid T, Tsaba A, van der Vliet A, Rasooly R, Goldkorn T. Ceramide-mediated apoptosis in lung epithelial cells is regulated by glutathione. Am J Respir Cell Mol Biol 2001; 25:676–684.
49. Hoidal JR. Reactive oxygen species and cell signaling. Am J Respir Cell Mol Biol 2001; 25:661–663.
50. Tyagi SC. Homocysteine redox receptor and regulation of extracellular matrix components in vascular cells. Am J Physiol 1998;274:C396–C405.
51. Lois M, Brown LA, Moss IM, Roman J, Giudot DM. Ethanol ingestion increases activation of matrix metalloproteinases in rat lungs during acute endotoxinemia. Am J Respir Crit Care Med 1999; 160:1354–1360.
52. Chen K-E, Reece LM, Leary JF. Mitochondrial glutathione modulates TNFalpha- induced endothelial cell dysfunction. Free Radic Biol Med 1999; 27: 100–109.
53. Choi AM, Elbon CL, Bruce SA, Bassett DJ. Messenger RNA levels of lung extracellular matrix proteins during ozone exposure. Lung 1994; 172:15–30.
54. Hagen K, Zhu C, Melefors O, Hultcrantz R. Susceptibility of cultured rat hepatocytes to oxidative stress by peroxides and iron. Int J Biochem Cell Biol 1999; 31:499–508.
55. Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, Roum JH, Czerski DB, Cantin AM, Crystal RG. Effect of glutathione aerosol on oxidantantioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338:215–216.
56. Cotgreave I, Moldeus P, Schuppe I. The metabolism of N-acetylcysteine by human endothelial cells. Biochem Pharmacol 1991; 42:13–16.
57. De Caro L, Ghizzi A, Costa R, Longo A, Ventresca GP, Lodola E. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittelforschung 1989; 39:382–386.
58. Olsson B, Johansson M, Gabrielsson J, Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 1988; 34:77–82.
59. Sjodin K, Nilsson E, Hallberg A, Tunek A. Metabolism of N-acetyl-L-cysteine. Some structural requirements for the deacetylation and consequences for the oral bioavailability. Biochem Pharmacol 1989; 38:3981–3985.
60. Cotgreave IA, Berggren M, Jones TW, Dawson J, Moldeus P. Gastrointestinal metabolism of N-acetylcysteine in the rat, including an assay for sulfite in biological systems. Biopharm Drug Dispos 1987; 8:377–386.
61. Issels RD, Nagele A, Eckert K, Wilmanns W. Promotion of cystine uptake and its utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol 1988; 37:881–888.
62. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:1557–1562.
63. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ 1991; 303:1026–1029.
64. Wagner PD, Mathieu-Costello O, Bebout DE, Gray AT, Natterson PD, Glennow C. Protection against pulmonary O2 toxicity by N-acetylcysteine. Eur Respir J 1989; 2:116–126.
65. Langley SC, Kelly FJ. N-acetylcysteine ameliorates hyperoxic lung injury in the preterm guinea pig. Biochem Pharmacol 1993; 45:841–846.
66. Hagiwara SI, Ishii Y, Kitamura S. Aerosolized administration of N-acetylcysteine attenuates lung fibrosis induced by bleomycin in mice. Am J Respir Crit Care Med 2000; 162:225–231
67. Wegener T, Hillerdal G, Ozesmi M, Sandhagen B, Saldeen T. Die Wirkung der N-Azetylzystein-Behandlung auf Paraquat-vergiftete Ratten. Atemw Lungenkrkh 1986; 7:303–306.
68. Lailey AF, Hill L, Lawston IW, Stanton D, Upshall DG. Protection by cysteine esters against chemically induced pulmonary oedema. Biochem Pharmacol 1991; 42 suppl:S47–S54.
69. Kennedy TP, Gordon GB, Paky A, McShane A, Adkinson NF, Peters SP, Friday K, Jackman W, Sciuto AM, Gurtner GH. Amiodarone causes acute oxidant lung injury in ventilated and perfused rabbit lungs. J Cardiovasc Pharmacol 1988; 12:23–36.
70. Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH. Protective effects of Nacetylcysteine treatment after phosgene exposure in rabbits. Am J Respir Crit Care Med 1995; 151:768–772.
71. Sala R, Moriggi E, Corvasce G, Morelli D. Protection by N-acetylcysteine against pulmonary endothelial cell damage induced by oxidant injury. Eur Respir J 1993; 6:440–446.
72. Giri SN, Hyde DM, Schiedt MJ. Effects of repeated administration of N-acetyl-Lcysteine on sulfhydryl levels of different tissues and bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 1988; 111:715–724.
73. van Klaveren RJ, Dinsdale D, Pype JL, Demedts M, Nemery B. N-acetylcysteine does not protect against type II cell injury after prolonged exposure to hyperoxia in rats. Am J Physiol 1997; 273:L548–L555.
74. Chan ED, Riches DWH, White CW. Redox paradox: effect of N-acetylcysteine and serum on oxidation reduction-sensitive mitogen-activated protein kinase signaling pathways. Am J Respir Cell Mol Biol 2001; 24:627–632.
75. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7:431–436.
76. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152:1055–1060.
77. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997; 156:1897–1901.